Feb 5, 2020 5:15pm EST Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD
Feb 4, 2020 7:00am EST Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences
Jan 29, 2020 4:15pm EST Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference
Jan 24, 2020 7:00am EST Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL
Jan 23, 2020 7:00am EST Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference
Dec 16, 2019 3:15pm EST Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study
Dec 11, 2019 4:05pm EST Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL
Dec 10, 2019 7:00am EST Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
